IMV INC

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch IMV INC and buy or sell other stocks, ETFs, and their options commission-free!

About IMVIF

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. 

CEO
Andrew Hall
CEOAndrew Hall
Employees
Employees
Headquarters
Dartmouth, Nova Scotia
HeadquartersDartmouth, Nova Scotia
Founded
2007
Founded2007
Employees
Employees

IMVIF Key Statistics

Market cap
23.42K
Market cap23.42K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.26K
Average volume1.26K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.0195
52 Week high$0.0195
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

With a market cap of 23.42K, IMV INC(IMVIF) trades at $0.00.

On 2026-04-27, IMV INC(IMVIF) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.26K.

Over the past 52 weeks, IMV INC(IMVIF) stock has traded between a high of $0.02 and a low of $0.00.

Over the past 52 weeks, IMV INC(IMVIF) stock has traded between a high of $0.02 and a low of $0.00.

People also own

Based on the portfolios of people who own IMVIF. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.